APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Conjugate Vaccine (PCV)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Pneumococcal Conjugate Vaccine (PCV) Market Analysis and Forecast 2026-2032

2 January 2026191 pages

Choose your research edition.

Industry ResearchPneumococcal Conjugate Vaccine (PCV) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Conjugate Vaccine (PCV) Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Pneumococcal Conjugate Vaccine (PCV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Conjugate Vaccine (PCV) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Conjugate Vaccine (PCV) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pneumococcal Conjugate Vaccine (PCV) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Pneumococcal Conjugate Vaccine (PCV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Pneumococcal Conjugate Vaccine (PCV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Pneumococcal Conjugate Vaccine (PCV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Pneumococcal Conjugate Vaccine (PCV) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Pneumococcal Conjugate Vaccine (PCV) include Sanofi, Merck, Pfizer, GSK, Zhifei Biologic, Walvax Biotechnology, Serum Institute of India and Royal (Wuxi) Bio-Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Pneumococcal Conjugate Vaccine (PCV), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pneumococcal Conjugate Vaccine (PCV), also provides the revenue of main regions and countries. Of the upcoming market potential for Pneumococcal Conjugate Vaccine (PCV), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pneumococcal Conjugate Vaccine (PCV) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pneumococcal Conjugate Vaccine (PCV) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pneumococcal Conjugate Vaccine (PCV) revenue, projected growth trends, production technology, application and end-user industry.

Pneumococcal Conjugate Vaccine (PCV) Segment by Company

Sanofi

Merck

Pfizer

GSK

Zhifei Biologic

Walvax Biotechnology

Serum Institute of India

Royal (Wuxi) Bio-Pharmaceutical

Pneumococcal Conjugate Vaccine (PCV) Segment by Type

10-valent Vaccine

13-valent Vaccine

23-valent Vaccine

7-valent Vaccine

Pneumococcal Conjugate Vaccine (PCV) Segment by Application

Child

Adult

Pneumococcal Conjugate Vaccine (PCV) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Conjugate Vaccine (PCV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Conjugate Vaccine (PCV) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Conjugate Vaccine (PCV).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Pneumococcal Conjugate Vaccine (PCV) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Pneumococcal Conjugate Vaccine (PCV) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumococcal Conjugate Vaccine (PCV) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 10-valent Vaccine Major Player Table 3. 13-valent Vaccine Major Player Table 4. 23-valent Vaccine Major Player Table 5. 7-valent Vaccine Major Player Table 6. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Child Major Player Table 8. Adult Major Player Table 9. Pneumococcal Conjugate Vaccine (PCV) Industry Trends Table 10. Pneumococcal Conjugate Vaccine (PCV) Industry Drivers Table 11. Pneumococcal Conjugate Vaccine (PCV) Industry Opportunities and Challenges Table 12. Pneumococcal Conjugate Vaccine (PCV) Industry Restraints Table 13. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region (2021-2026) Table 16. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region (2027-2032) Table 18. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Players (2021-2026) Table 20. Global Pneumococcal Conjugate Vaccine (PCV) Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Pneumococcal Conjugate Vaccine (PCV) Key Players Headquarters & Area Served Table 22. Global Pneumococcal Conjugate Vaccine (PCV) Players, Product Type & Application Table 23. Global Pneumococcal Conjugate Vaccine (PCV) Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Pneumococcal Conjugate Vaccine (PCV) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Type (2021-2026) Table 30. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Type (2027-2032) Table 31. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Application (2021-2026) Table 35. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Application (2027-2032) Table 36. Sanofi Company Information Table 37. Sanofi Business Overview Table 38. Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 40. Sanofi Recent Development Table 41. Merck Company Information Table 42. Merck Business Overview Table 43. Merck Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 45. Merck Recent Development Table 46. Pfizer Company Information Table 47. Pfizer Business Overview Table 48. Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 50. Pfizer Recent Development Table 51. GSK Company Information Table 52. GSK Business Overview Table 53. GSK Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 55. GSK Recent Development Table 56. Zhifei Biologic Company Information Table 57. Zhifei Biologic Business Overview Table 58. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 60. Zhifei Biologic Recent Development Table 61. Walvax Biotechnology Company Information Table 62. Walvax Biotechnology Business Overview Table 63. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 65. Walvax Biotechnology Recent Development Table 66. Serum Institute of India Company Information Table 67. Serum Institute of India Business Overview Table 68. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 70. Serum Institute of India Recent Development Table 71. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 72. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 73. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 75. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 76. North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026) & (US$ Million) Table 77. North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032) & (US$ Million) Table 78. North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026) & (US$ Million) Table 79. North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032) & (US$ Million) Table 80. North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021-2026) & (US$ Million) Table 82. North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (US$ Million) & (2027-2032) Table 83. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026) & (US$ Million) Table 84. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032) & (US$ Million) Table 85. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026) & (US$ Million) Table 86. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032) & (US$ Million) Table 87. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021-2026) & (US$ Million) Table 89. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (US$ Million) & (2027-2032) Table 90. China Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026) & (US$ Million) Table 91. China Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032) & (US$ Million) Table 92. China Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026) & (US$ Million) Table 93. China Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032) & (US$ Million) Table 94. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026) & (US$ Million) Table 95. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032) & (US$ Million) Table 96. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026) & (US$ Million) Table 97. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Region (US$ Million) & (2021-2026) Table 100. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Region (US$ Million) & (2027-2032) Table 101. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026) & (US$ Million) Table 102. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032) & (US$ Million) Table 103. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026) & (US$ Million) Table 104. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032) & (US$ Million) Table 105. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021-2026) & (US$ Million) Table 107. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (US$ Million) & (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Pneumococcal Conjugate Vaccine (PCV) Image Figure 2. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share 2021 VS 2025 VS 2032 Figure 4. 10-valent Vaccine Image Figure 5. 13-valent Vaccine Image Figure 6. 23-valent Vaccine Image Figure 7. 7-valent Vaccine Image Figure 8. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share 2021 VS 2025 VS 2032 Figure 10. Child Image Figure 11. Adult Image Figure 12. Global Pneumococcal Conjugate Vaccine (PCV) Market Size (US$ Million) & (2021-2032) Figure 13. Global Pneumococcal Conjugate Vaccine (PCV) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Pneumococcal Conjugate Vaccine (PCV) Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Type (2021-2032) Figure 20. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Application (2021-2032) Figure 23. North America Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Type (2021-2032) Figure 25. North America Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Application (2021-2032) Figure 26. North America Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Country (2021-2032) Figure 27. United States Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Type (2021-2032) Figure 32. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Application (2021-2032) Figure 33. Europe Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Country (2021-2032) Figure 34. Germany Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Type (2021-2032) Figure 44. China Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Application (2021-2032) Figure 45. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Type (2021-2032) Figure 47. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Application (2021-2032) Figure 48. Asia Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Region (2021-2032) Figure 49. Japan Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Type (2021-2032) Figure 57. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Application (2021-2032) Figure 58. SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Country (2021-2032) Figure 59. Brazil Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Pneumococcal Conjugate Vaccine (PCV) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 10-valent Vaccine
  • 13-valent Vaccine
  • 23-valent Vaccine
  • 7-valent Vaccine
Applications
  • Child
  • Adult
Companies covered
  • Sanofi
  • Merck
  • Pfizer
  • GSK
  • Zhifei Biologic
  • Walvax Biotechnology
  • Serum Institute of India
  • Royal (Wuxi) Bio-Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pneumococcal Conjugate Vaccine (PCV) Market by Type
  3. 1.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 10-valent Vaccine
  5. 1.2.3 13-valent Vaccine
  6. 1.2.4 23-valent Vaccine
  7. 1.2.5 7-valent Vaccine
  8. 1.3 Pneumococcal Conjugate Vaccine (PCV) Market by Application
  9. 1.3.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Child
  11. 1.3.3 Adult
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Pneumococcal Conjugate Vaccine (PCV) Market Dynamics
  1. 2.1 Pneumococcal Conjugate Vaccine (PCV) Industry Trends
  2. 2.2 Pneumococcal Conjugate Vaccine (PCV) Industry Drivers
  3. 2.3 Pneumococcal Conjugate Vaccine (PCV) Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Conjugate Vaccine (PCV) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Perspective (2021-2032)
  2. 3.2 Global Pneumococcal Conjugate Vaccine (PCV) Growth Trends by Region
  3. 3.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2021-2026)
  5. 3.2.3 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Players
  2. 4.1.1 Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Players (2021-2026)
  3. 4.1.2 Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Pneumococcal Conjugate Vaccine (PCV) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pneumococcal Conjugate Vaccine (PCV) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Pneumococcal Conjugate Vaccine (PCV) Key Players Headquarters & Area Served
  7. 4.4 Global Pneumococcal Conjugate Vaccine (PCV) Players, Product Type & Application
  8. 4.5 Global Pneumococcal Conjugate Vaccine (PCV) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Pneumococcal Conjugate Vaccine (PCV) Market CR5 and HHI
  11. 4.6.3 2025 Pneumococcal Conjugate Vaccine (PCV) Tier 1, Tier 2, and Tier 3
5 Pneumococcal Conjugate Vaccine (PCV) Market Size by Type
  1. 5.1 Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2032)
  3. 5.3 Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Type (2021-2032)
6 Pneumococcal Conjugate Vaccine (PCV) Market Size by Application
  1. 6.1 Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2032)
  3. 6.3 Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Merck
  8. 7.2.1 Merck Company Information
  9. 7.2.2 Merck Business Overview
  10. 7.2.3 Merck Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  12. 7.2.5 Merck Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 GSK
  20. 7.4.1 GSK Company Information
  21. 7.4.2 GSK Business Overview
  22. 7.4.3 GSK Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  24. 7.4.5 GSK Recent Developments
  25. 7.5 Zhifei Biologic
  26. 7.5.1 Zhifei Biologic Company Information
  27. 7.5.2 Zhifei Biologic Business Overview
  28. 7.5.3 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  30. 7.5.5 Zhifei Biologic Recent Developments
  31. 7.6 Walvax Biotechnology
  32. 7.6.1 Walvax Biotechnology Company Information
  33. 7.6.2 Walvax Biotechnology Business Overview
  34. 7.6.3 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  36. 7.6.5 Walvax Biotechnology Recent Developments
  37. 7.7 Serum Institute of India
  38. 7.7.1 Serum Institute of India Company Information
  39. 7.7.2 Serum Institute of India Business Overview
  40. 7.7.3 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  42. 7.7.5 Serum Institute of India Recent Developments
  43. 7.8 Royal (Wuxi) Bio-Pharmaceutical
  44. 7.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  45. 7.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  46. 7.8.3 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  48. 7.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Pneumococcal Conjugate Vaccine (PCV) Revenue (2021-2032)
  2. 8.2 North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2032)
  3. 8.2.1 North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026)
  4. 8.2.2 North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032)
  5. 8.3 North America Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Type (2021-2032)
  6. 8.4 North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2032)
  7. 8.4.1 North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026)
  8. 8.4.2 North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032)
  9. 8.5 North America Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Application (2021-2032)
  10. 8.6 North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Country
  11. 8.6.1 North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021-2026)
  13. 8.6.3 North America Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue (2021-2032)
  2. 9.2 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032)
  5. 9.3 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032)
  9. 9.5 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Country
  11. 9.6.1 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Pneumococcal Conjugate Vaccine (PCV) Revenue (2021-2032)
  2. 10.2 China Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2032)
  3. 10.2.1 China Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026)
  4. 10.2.2 China Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032)
  5. 10.3 China Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Type (2021-2032)
  6. 10.4 China Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2032)
  7. 10.4.1 China Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026)
  8. 10.4.2 China Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032)
  9. 10.5 China Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue (2021-2032)
  2. 11.2 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032)
  5. 11.3 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032)
  9. 11.5 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Country
  11. 11.6.1 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue (2021-2032)
  2. 12.2 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Country
  11. 12.6.1 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Pneumococcal Conjugate Vaccine (PCV) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst